Connexins: New genes in atherosclerosis

Annals of Medicine

Volumn 39, Issue 6, 2007, Pages 402-411

  Chadjichristos, Christos E ^a   Kwak, Brenda R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Connexin; Endothelium; Gap junction; Leukocytes; Smooth muscle cells; Vascular wall

Indexed keywords

CONNEXIN 43; GAP JUNCTION PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL RUPTURE; BLOOD VESSEL WALL; CELL COMMUNICATION; ENDOTHELIAL DYSFUNCTION; GAP JUNCTION; HUMAN; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE CELL; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; BLOOD VESSEL; CELL JUNCTION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CELL COMMUNICATION; CONNEXINS; ENDOTHELIUM, VASCULAR; GAP JUNCTIONS; MICE;

EID: 38549123050     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890701436757     Document Type: Article

References (86)

1. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791-804.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.
3. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-16.
4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
6. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-81.
7. Gimbrone MA Jr. Endothelial dysfunction, hemodynamic forces, and atherosclerosis. Thromb Haemost. 1999; 82:722-6.
8. Konstantopoulos K, McIntire LV. Effects of fluid dynamic forces on vascular cell adhesion. J Clin Invest. 1996;98:2661-5.
9. Chien S, Li S, Shyy YJ. Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension. 1998;31:162-9.
10. Davies PF, Spaan JA, Krams R. Shear stress biology of the endothelium. Ann Biomed Eng. 2005;33:1714-8.
11. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-19.
12. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-8.
13. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006;69:614-24.
14. Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev. 2003;83:1359-400.
15. Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res. 2004;62:228-32.
16. Harris AL. Emerging issues of connexin channels: biophysics fills the gap. Q Rev Biophys. 2001;34:325-472.
17. Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 2003;4:285-94.
18. Elfgang C, Eckert R, Lichtenberg-Frate H, Butterweck A, Traub O, Klein RA, et al. Specific permeability and selective formation of gap junction channels in connexin-transfected HeLa cells. J Cell Biol. 1995;129:805-17.
19. Kwak BR, Hermans MM, De Jonge HR, Lohmann SM, Jongsma HJ, Chanson M. Differential regulation of distinct types of gap junction channels by similar phosphorylating conditions. Mol Biol Cell. 1995;6:1707-19.
20. Goldberg GS, Lampe PD, Nicholson BJ. Selective transfer of endogenous metabolites through gap junctions composed of different connexins. Nat Cell Biol. 1999;1:457-9.
21. Bevans CG, Kordel M, Rhee SK, Harris AL. Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem. 1998;273:2808-16.
22. Hill CE, Phillips JK, Sandow SL. Heterogeneous control of blood flow amongst different vascular beds. Med Res Rev. 2001;21:1-60.
23. Figueroa XF, Isakson BE, Duling BR. Connexins: gaps in our knowledge of vascular function. Physiology (Bethesda). 2004;19:277-84.
24. De Wit C, Hoepfl B, Wolfle SE. Endothelial mediators and communication through vascular gap junctions. Biol Chem. 2006;387:3-9.
25. van Kempen MJ, Jongsma HJ. Distribution of connexin37, connexin40 and connexin43 in the aorta and coronary artery of several mammals. Histochem Cell Biol. 1999;112:479-86.
26. Gabriels JE, Paul DL. Connexin43 is highly localized to sites of disturbed flow in rat aortic endothelium but connexin37 and connexin40 are more uniformly distributed. Circ Res. 1998;83:636-43.
27. Theis M, de Wit C, Schlaeger TM, Eckardt D, Kruger O, Doring B, et al. Endothelium-specific replacement of the connexin43 coding region by a lacZ reporter gene. Genesis. 2001;29:1-13.
28. Little TL, Beyer EC, Duling BR. Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth muscle and endothelium in vivo. Am J Physiol. 1995;268:H729-39.
29. Haefliger JA, Polikar R, Schnyder G, Burdet M, Sutter E, Pexieder T, et al. Connexin37 in normal and pathological development of mouse heart and great arteries. Dev Dyn. 2000;218:331-44.
30. Beny JL. Information Networks in the Arterial Wall. News Physiol Sci. 1999;14:68-73.
31. Kwak BR, Pepper MS, Gros DB, Meda P. Inhibition of endothelial wound repair by dominant negative connexin inhibitors. Mol Biol Cell. 2001;12:831-45.
32. de Wit C, Roos F, Bolz SS, Kirchhoff S, Kruger O, Willecke K, et al. Impaired conduction of vasodilation along arterioles in connexin40-deficient mice. Circ Res. 2000;86:649-55.
33. de Wit C, Roos F, Bolz SS, Pohl U. Lack of vascular connexin 40 is associated with hypertension and irregular arteriolar vasomotion. Physiol Genomics. 2003;13:169-77.
34. Liao Y, Day KH, Damon DN, Duling BR. Endothelial cellspecific knockout of connexin 43 causes hypotension and bradycardia in mice. Proc Natl Acad Sci USA. 2001;98:9989-94.
35. Kruger O, Plum A, Kim JS, Winterhager E, Maxeiner S, Hallas G, et al. Defective vascular development in connexin 45-deficient mice. Development. 2000;127:4179-93.
36. Simon AM, Goodenough DA, Li E, Paul DL. Female infertility in mice lacking connexin 37. Nature. 1997;385:525-29.
37. Figueroa XF, Isakson BE, Duling BR. Vascular gap junctions in hypertension. Hypertension. 1996;48:804-11.
38. Simon AM, McWhorter AR. Vascular abnormalities in mice lacking the endothelial gap junction proteins connexin37 and connexin40. Dev Biol. 2002;251:206-20.
39. Blackburn JP, Peters NS, Yeh HI, Rothery S, Green CR, Severs NJ. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1219-28.
40. Polacek D, Bech F, McKinsey, Davies PF. Connexin43 gene expression in the rabbit arterial wall: effects of hypercholesterolemia, balloon injury and their combination. J Vasc Res. 1996;34:19-30.
41. Kwak BR, Mulhaupt F, Veillard N, Gros DB, Mach F. Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22:225-30.
42. Yeh HI, Lu CS, Wu YJ, Chen CC, Hong RC, Ko YS, et al. Reduced expression of endothelial connexin37 and connexin40 in hyperlipidemic mice: recovery of connexin37 after 7-day simvastatin treatment. Arterioscler Thromb Vasc Biol. 2003;23:1391-7.
43. Cowan DB, Lye SJ, Langille BL. Regulation of vascular connexin43 gene expression by mechanical loads. Circ Res. 1998;82:786-93.
44. DePaola N, Davies PF, Pritchard WF Jr, Florez L, Harbeck N, Polacek DC. Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro. Proc Natl Acad Sci USA. 1999;96:3154-59.
45. Davies PF, Shi C, Depaola N, Helmke BP, Polacek DC. Hemodynamics and the focal origin of atherosclerosis: a spatial approach to endothelial structure, gene expression, and function. Ann N Y Acad Sci. 2001;947:7-16.
46. Kwak BR, Silacci P, Stergiopulos N, Hayoz D, Meda P. Shear stress and cyclic circumferential stretch, but not pressure, alter connexin43 expression in endothelial cells. Cell Commun Adhes. 2005;12:261-70.
47. Meyer R, Malewicz B, Baumann WJ, Johnson RG. Increased gap junction assembly between cultured cells upon cholesterol supplementation. J Cell Sci. 1990;96:231-8.
48. Meyer RA, Lampe PD, Malewicz B, Baumann WJ, Johnson RG. Enhanced gap junction formation with LDL and apolipoprotein B. Exp Cell Res. 1991;196:72-81.
49. Paulson AF, Lampe PD, Meyer RA, TenBroek E, Atkinson MM, Walseth TF, et al. Cyclic AMP and LDL trigger a rapid enhancement in gap junction assembly through a stimulation of connexin trafficking. J Cell Sci. 2000;113:3037-49.
50. Bastiaanse EM, Jongsma HJ, van der Laarse A, Takens-Kwak BR. Heptanol-induced decrease in cardiacgap junctional conductance is mediated by a decrease in the fluidity of membranous cholesterol-rich domains. J Membr Biol. 1993;136:135-45.
51. Isakson BE, Kronke G, Kadl A, Leitinger N, Duling BR. Oxidized phospholipids alter vascular connexin expression, phosphorylation, and heterocellular communication. Arterioscler Thromb Vasc Biol. 2006;26:2216-21.
52. De Maio A, Vega VL, Contreras JE. Gap junctions, homeostasis, and injury. J Cell Physiol. 2002;191:269-82.
53. Chanson M, Derouette JP, Roth I, Foglia B, Scerri I, Dudez T, et al. Gap junctional communication in tissue inflammation and repair. Biochim Biophys Acta. 2005;1711:197-207.
54. Hu VW, Xie HQ. Interleukin-1 alpha suppresses gap junction-mediated intercellular communication in human endothelial cells. Exp Cell Res. 1994;213:218-23.
55. van Rijen HV, van Kempen MJ, Postma S, Jongsma HJ. Tumour necrosis factor alpha alters the expression of connexin43, connexin40, and connexin37 in human umbilical vein endothelial cells. Cytokine. 1998;10:258-64.
56. Mensink A, de Haan LH, Lakemond CM, Koelman CA, Koeman JH. Inhibition of gap junctional intercellular communication between primary human smooth muscle cells by tumor necrosis factor alpha. Carcinogenesis. 1995;16:2063-7.
57. Hu J, Cotgreave IA. Differential regulation of gap junctions by proinflammatory mediators in vitro. J Clin Invest. 1997;99:2312-6.
58. Zahler S, Hoffmann A, Gloe T, Pohl U. Gap-junctional coupling between neutrophils and endothelial cells: a novel modulator of transendothelial migration. J Leukoc Biol. 2003;73:118-26.
59. Scerri I, Tabary O, Dudez T, Jacquot J, Foglia B, Suter S, et al. Gap junctional communication does not contribute to the interaction between neutrophils and airway epithelial cells. Cell Commun Adhes. 2006;13:1-12.
60. Eugenin EA, Branes MC, Berman JW, Saez JC. TNF-alpha plus IFN-gamma induce connexin43 expression and formation of gap junctions between human monocytes/ macrophages that enhance physiological responses. J Immunol. 2003;170:1320-8.
61. Oviedo-Orta E, Errington RJ, Evans WH. Gap junction intercellular communication during lymphocyte transendothelial migration. Cell Biol Int. 2002;26:253-63.
62. Wong CW, Christen T, Kwak BR. Connexins in leukocytes: shuttling messages? Cardiovasc Res. 2004;62:357-67.
63. Wong CW, Christen T, Roth I, Chadjichristos CE, Derouette JP, Foglia BF, et al. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med. 2006;12:950-4.
64. Boerma M, Forsberg L, Van Zeijl L, Morgenstern R, De Faire U, Lemne C, et al. A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development. J Intern Med. 1999;246:211-18.
65. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347:1916-23.
66. Yeh HI, Chou Y, Liu HF, Chang SC, Tsai CH. Connexin37 gene polymorphism and coronary artery disease in Taiwan. Int J Cardiol. 2001;81:251-5.
67. Listi F, Candore G, Lio D, Russo M, Colonna-Romano G, Caruso M, et al. Association between C1019T polymorphism of connexin37 and acute myocardial infarction: a study in patients from Sicily. Int J Cardiol. 2005;102:269-71.
68. Wong CW, Christen T, Pfenniger A, James RW, Kwak BR. Do allelic variants of the connexin37 1019 gene polymorphism differentially predict for coronary artery disease and myocardial infarction? Atherosclerosis. 2007;191:355-61.
69. Rennick RE, Connat JL, Burnstock G, Rothery S, Severs NJ, Green CR. Expression of connexin43 gap junctions between cultured vascular smooth muscle cells is dependent upon phenotype. Cell Tissue Res. 1993;271:323-32.
70. Kurjiaka DT, Steele TD, Olsen MV, Burt JM. Gap junction permeability is diminished in proliferating vascular smooth muscle cells. Am J Physiol. 1998;275:C1674-82.
71. Polacek D, Lal R, Volin MV, Davies PF. Gap junctional communication between vascular cells. Induction of connexin43 messenger RNA in macrophage foam cells of atherosclerotic lesions. Am J Pathol. 1993;142:593-606.
72. Reaume AG, de Sousa PA, Kulkarni S, Langille BL, Zhu D, Davies TC, et al. Cardiac malformation in neonatal mice lacking connexin43. Science. 1995;267:1831-4.
73. Guerrero PA, Schuessler RB, Davis LM, Beyer EC, Johnson CM, Yamada KA, et al. Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest. 1997;99:1991-8.
74. Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation. 2003;107:1033-9.
75. Wong CW, Burger F, Pelli G, Mach F, Kwak BR. Dual benefit of reduced Cx43 on atherosclerosis in LDL receptor-deficient mice. Cell Commun Adhes. 2003;10:395-400.
76. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1-10.
77. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771-7.
78. Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med. 2005;15:202-6.
79. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257-62.
80. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandablestent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489-95.
81. Lee SS, Price MJ, Wong GB, Valencia R, Damani S, Sawhney N, et al. Early-and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. Am J Cardiol. 2006;98:1345-8.
82. Yeh HI, Lupu F, Dupont E, Severs NJ. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Arterioscler Thromb Vasc Biol. 1997;17:3174-84.
83. Plenz G, Ko YS, Yeh HI, Eschert H, Sindermann JR, Dorszewski A, et al. Upregulation of connexin43 gap junctions between neointimal smooth muscle cells. Eur J Cell Biol. 2004;83:521-30.
84. Wang LH, Chen JZ, Sun YL, Zhang FR, Zhu JH, Hu SJ, et al. Statins reduce connexin40 and connexin43 expression in atherosclerotic aorta of rabbits. Int J Cardiol. 2005;100:467-75.
85. Chadjichristos CE, Matter CM, Roth I, Sutter E, Pelli G, Luscher TF, et al. Reduced connexin43 expression limits neointima formation after balloon distension injury in hypercholesterolemic mice. Circulation. 2006;113:2835-43.
86. Chadjichristos CE, Roth I, Hoepfl B, van Veen TA, Deutsch U, van Kempen MJ, et al. Increased development of atherosclerosis in mice with endothelial-specific deletion of connexin40. Circulation. 2005;112:II-142 (abstract).